샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782913

세계의 미세잔존질환 검사 시장

Minimal Residual Disease Testing
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 383 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미세잔존질환 검사 세계 시장은 2030년까지 44억 달러에 달할 전망

2024년에 23억 달러로 추정되는 미세잔존질환 검사 세계 시장은 2024년부터 2030년까지 CAGR 11.6%로 성장하여 2030년에는 44억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 유세포 분석 기술은 CAGR 13.0%를 기록하며 분석 기간 종료까지 21억 달러에 달할 것으로 예측됩니다. 중합효소 연쇄 반응 기술 분야의 성장률은 분석 기간 CAGR로 11.8%로 추정됩니다.

미국 시장은 6억 2,110만 달러로 추정, 중국은 CAGR 15.8%로 성장할 것으로 예측

미국의 미세잔존질환 검사 시장은 2024년에 6억 2,110만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 15.8%로 2030년까지 9억 2,500만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 8.3%와 10.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.2%로 성장할 것으로 예측됩니다.

세계의 미세잔존질환 검사 시장 - 주요 동향과 촉진요인 정리

미세잔존질환 검사란 무엇이며, 왜 중요한가?

미세잔존질환(MRD) 검사는 표준 진단 툴로는 검출할 수 없는, 치료 후 환자 체내에 남아있는 극소량의 암세포를 검출하기 위해 사용되는 고감도 검사법을 말합니다. MRD 검사는 암 치료의 효과를 판단하고, 재발 위험을 예측하며, 이후 치료 방침을 결정하는 데 매우 중요합니다. 백혈병, 림프종, 다발성 골수종 등의 혈액암에서 특히 중요하며, 임상적 관해 후에도 미량의 비정상 세포가 체내에 남아있을 수 있습니다. MRD 검사는 이러한 잔존 세포를 식별함으로써 임상의가 치료 계획을 조정하고, 질병의 재발을 모니터링하며, 환자의 예후를 개선하는 데 도움이 되는 귀중한 정보를 제공합니다.

MRD 검사에 사용되는 기술로는 유세포 분석, 중합효소 연쇄 반응(PCR), 차세대 염기서열 분석(NGS) 등이 있습니다. 이 방법들은 기존의 영상 검사나 혈액 검사보다 훨씬 더 높은 민감도로 혈액이나 골수 샘플의 이상을 감지할 수 있습니다. 예를 들어, PCR법은 특정 암과 관련된 특정 유전자 마커를 식별할 수 있는 반면, NGS법은 보다 광범위한 암세포의 돌연변이 및 유전자 변화를 밝힐 수 있습니다. 이러한 잔존 세포를 높은 정확도로 검출할 수 있는 능력은 혈액 악성 종양 관리에 혁명을 가져올 것이며, 조기 개입을 위한 도구와 현재 진행 중인 치료의 성공 여부를 측정할 수 있는 방법을 제공할 것입니다.

미세잔존질환 검사 시장이 성장하는 이유는?

MRD 검사 세계 시장은 암 발병률 증가, 검사 기술의 발전, 맞춤형 의료의 중요성 등 몇 가지 중요한 요인으로 인해 빠르게 성장하고 있습니다. 암, 특히 백혈병 및 림프종과 같은 혈액암에 대한 전 세계 부담이 증가함에 따라 보다 정확한 진단 및 모니터링 도구에 대한 수요가 증가하고 있습니다. 의료 시스템이 생존율과 치료 성적 향상을 목표로 하는 가운데, MRD 검사는 암 관리에 필수적인 요소로 자리 잡고 있습니다. 기존 영상 진단 기술로는 볼 수 없었던 암을 가장 초기에 발견할 수 있다는 것은 임상의와 환자 모두에게 획기적인 일입니다.

또한, 조기 재발 발견의 이점과 맞춤형 치료 전략에서 MRD 검사의 역할에 대한 인식이 높아지면서 시장을 더욱 견인하고 있습니다. 맞춤의료는 유전적 요인이나 다양한 치료법에 대한 반응성 등 환자 개개인의 질환의 특이적 특성에 맞게 치료를 조정하는 데 중점을 두고 있습니다. MRD 검사는 임상의가 실시간으로 치료 계획을 조정하고 환자가 가장 효과적인 치료를 받을 수 있도록 돕고 불필요한 치료를 줄이는 데 도움이 되기 때문에 이 접근법에서 매우 중요한 역할을 합니다. 이러한 맞춤형 치료의 발전은 보다 효과적이고 정확한 암 치료에 대한 환자들의 요구가 높아지면서 전 세계적으로 MRD 검사의 채택을 가속화하고 있습니다.

MRD 검사의 미래를 형성하는 주요 동향은 무엇인가?

MRD 검사의 미래는 기술 발전, 규제 발전, 액체 생검 기술로의 전환 등 몇 가지 혁신적 트렌드에 의해 형성되고 있습니다. 가장 중요한 트렌드 중 하나는 MRD 검출법의 민감도와 정확도가 지속적으로 향상되고 있다는 점입니다. 예를 들어, 차세대 염기서열 분석(NGS)과 디지털 PCR은 더욱 정교해져 현재 100만 개 중 1개 정도의 낮은 수준의 암세포에서 MRD를 검출할 수 있게 되었고, 미세잔존질환을 장기적으로 모니터링하는 능력이 크게 향상되었습니다. 이러한 기술 혁신은 재발을 조기에 발견할 수 있도록 도와주며, 임상의가 화학요법 추가, 골수 이식 등 치료 계획을 조정할 것인지에 대해 보다 현명한 결정을 내릴 수 있도록 돕습니다.

또 다른 중요한 트렌드는 액체 생검 기술의 보급입니다. 기존 MRD 검사는 골수 흡인 등 침습적인 시술이 필요했습니다. 하지만 혈액 샘플을 검사하는 액체 생검은 침습성이 낮고, 간편하며, 실시간으로 결과를 얻을 수 있어 널리 사용되고 있습니다. 이 방법은 생검을 반복할 필요가 없고, 빈번한 검사가 가능하기 때문에 초기 치료를 마친 환자나 관해기에 있는 환자의 모니터링에 특히 매력적입니다. 또한, 액체 생검은 혈액암 이외의 다른 암에서도 비침습적 MRD 검사의 길을 열어 종양학에서 MRD의 적용 범위를 넓혀가고 있습니다.

MRD 검사 시장의 성장 촉진요인은 무엇인가?

미세잔존질환 검사 시장의 성장은 분자생물학의 발전, 암 감시의 중요성 증가, 정밀의료의 채택 증가 등 여러 요인에 기인하고 있습니다. 암 생물학에 대한 이해가 깊어짐에 따라, 보다 민감하고 신뢰할 수 있는 결과를 제공하는 첨단 검사법을 개발할 수 있는 능력도 향상되고 있습니다. 차세대 시퀀싱 및 PCR과 같은 분자 기술의 발전으로 혈류 및 골수 내 미량의 암세포를 검출할 수 있게 되어 질병의 진행과 완화를 보다 정확하게 모니터링할 수 있게 되었습니다.

정밀의료로의 전환도 MRD 검사 수요 증가의 중요한 원동력입니다. 개인별 맞춤치료가 확산되고 있는 가운데 MRD 검사는 치료의 효과를 평가하고 환자의 결과를 예측할 수 있는 귀중한 도구가 될 수 있습니다. MRD 검사는 재발하기 전에 잔존 병변을 확인함으로써 임상의가 적시에 개입하고 치료 계획을 수정하여 결과를 최적화할 수 있도록 돕습니다. 또한, 혈액암의 유병률 증가와 더 나은 치료법을 찾는 환자의 증가는 MRD 검사 서비스에 대한 수요를 촉진하고 있습니다. 의료 서비스 제공자, 특히 종양 센터에서 MRD 검사를 일상적인 암 치료에 통합하는 경향이 증가하고 있으며, 장기적인 암 관리 전략의 필수적인 부분으로 자리 잡고 있습니다.

마지막으로, 규제 당국의 승인과 상환 지원도 시장 성장에 중요한 역할을 하고 있습니다. FDA 및 기타 규제 기관은 항암제의 일상적인 임상시험의 일환으로 MRD 검사를 승인하기 시작했으며, 이는 임상 연구와 진료 모두에서 MRD 검사의 통합을 촉진하고 있습니다. 또한 MRD 검사에 보험을 적용하는 보험사도 늘고 있어 MRD 검사 보급에 더욱 박차를 가하고 있습니다. 이러한 요인들이 지속적으로 일치함에 따라 MRD 검사 시장은 상승세를 유지하고, 암 치료의 혁신을 촉진하고, 환자에게 장기 생존과 삶의 질을 향상시킬 수 있는 기회를 제공할 것으로 예상됩니다.

부문

기술(유세포 분석 기술, 중합효소 연쇄 반응 기술, 차세대 시퀀싱 기술, 기타 기술), 암종(혈액 악성 종양, 고형 종양), 최종사용자(병원·전문 클리닉, 진단 연구소, 학술·연구기관, 기타 최종사용자)

조사 대상 기업 사례

  • Adaptive Biotechnologies Corporation
  • ArcherDX, Inc.
  • ARUP Laboratories Inc.
  • Asuragen Inc.
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health
  • Invitae Corporation
  • Invivoscribe Inc.
  • Labcorp Inc.
  • Laboratory Corporation of America Holdings
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoOne
  • QIAGEN N.V.
  • Quest Diagnostics
  • Sysmex Corporation

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.08

Global Minimal Residual Disease Testing Market to Reach US$4.4 Billion by 2030

The global market for Minimal Residual Disease Testing estimated at US$2.3 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2024-2030. Flow Cytometry Technology, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Polymerase Chain Reaction Technology segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$621.1 Million While China is Forecast to Grow at 15.8% CAGR

The Minimal Residual Disease Testing market in the U.S. is estimated at US$621.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$925.0 Million by the year 2030 trailing a CAGR of 15.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Minimal Residual Disease Testing Market - Key Trends & Drivers Summarized

What Is Minimal Residual Disease Testing and Why Is It Important?

Minimal Residual Disease (MRD) testing refers to highly sensitive testing methods used to detect very small amounts of cancerous cells remaining in a patient’s body after treatment, which are not detectable by standard diagnostic tools. MRD testing is critical in determining the effectiveness of cancer treatment, predicting the risk of relapse, and guiding subsequent therapy decisions. It is particularly important in hematologic cancers such as leukemia, lymphoma, and multiple myeloma, where microscopic amounts of abnormal cells can persist in the body even after clinical remission. By identifying these remaining cells, MRD testing provides clinicians with valuable information that can help tailor treatment plans, monitor disease recurrence, and improve patient outcomes.

Techniques used for MRD testing include flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). These methods allow for the detection of abnormalities in blood or bone marrow samples at a much higher sensitivity level than traditional imaging or blood tests. For instance, PCR can identify specific genetic markers associated with certain cancers, while NGS can uncover mutations or genetic alterations in a broader range of cancer cells. The ability to detect these residual cells with high precision has revolutionized the management of hematologic malignancies, offering both a tool for early intervention and a way to gauge the success of ongoing treatments.

Why Is the Minimal Residual Disease Testing Market Growing?

The global market for MRD testing is expanding rapidly due to several key factors, including increasing cancer incidence, advancements in testing technology, and a greater emphasis on personalized medicine. The rising global burden of cancer, particularly hematologic cancers such as leukemia and lymphoma, has spurred demand for more accurate diagnostic and monitoring tools. As healthcare systems aim to improve survival rates and treatment outcomes, MRD testing has become an essential part of cancer management. The ability to detect cancer at its earliest stages, even when it is not visible through conventional imaging techniques, is a game-changer for clinicians and patients alike.

Moreover, the growing awareness of the benefits of early relapse detection and the role of MRD testing in personalized treatment strategies is further driving the market. Personalized medicine focuses on tailoring treatment to the specific characteristics of each patient’s disease, including genetic factors and how the disease responds to various therapies. MRD testing plays a pivotal role in this approach, as it helps clinicians adjust treatment plans in real-time, ensuring that patients receive the most effective therapies and reducing unnecessary treatments. These advancements in personalized care, coupled with a rise in patient demand for more effective and precise cancer treatments, are accelerating the adoption of MRD testing worldwide.

What Key Trends Are Shaping the Future of MRD Testing?

The future of MRD testing is being shaped by several transformative trends, notably technological advancements, regulatory developments, and a shift toward liquid biopsy techniques. One of the most significant trends is the continuous improvement of sensitivity and accuracy in MRD detection methods. Next-generation sequencing (NGS) and digital PCR, for example, are becoming more refined and are now able to detect MRD at levels as low as one cancer cell in a million, significantly improving the ability to monitor minimal residual disease over time. These innovations are enhancing early relapse detection and allowing clinicians to make more informed decisions about whether to adjust treatment plans, such as introducing additional chemotherapy or bone marrow transplants.

Another key trend is the increasing popularity of liquid biopsy techniques. Traditionally, MRD testing required invasive procedures such as bone marrow aspirates. However, liquid biopsy, which involves testing blood samples, is becoming more widely used due to its less invasive nature, convenience, and ability to provide real-time results. This approach is especially attractive in monitoring patients who have completed initial treatment or those in remission, as it can be used for frequent testing without the need for repeated biopsies. Liquid biopsies are also paving the way for non-invasive MRD testing in other cancers beyond hematologic malignancies, expanding the scope of MRD applications in oncology.

What Are the Key Drivers of Growth in the MRD Testing Market?

The growth in the minimal residual disease testing market is driven by several factors, including advancements in molecular biology, an increasing focus on cancer surveillance, and the rising adoption of precision medicine. As our understanding of cancer biology deepens, so does our ability to develop sophisticated testing methods that provide more sensitive and reliable results. The growth of molecular techniques, such as next-generation sequencing and PCR, has made it possible to detect minute amounts of cancer cells in the bloodstream or bone marrow, allowing for more accurate monitoring of disease progression and remission.

The shift toward precision medicine is another key driver behind the increased demand for MRD testing. With personalized treatments becoming more prevalent, MRD testing provides a valuable tool for assessing the effectiveness of therapies and predicting patient outcomes. By identifying residual disease before relapse occurs, MRD testing enables clinicians to make timely interventions and modify treatment plans to optimize outcomes. Furthermore, the growing prevalence of hematologic cancers, coupled with an increasing number of patients seeking better management options, is driving demand for MRD testing services. Healthcare providers, particularly in oncology centers, are increasingly integrating MRD testing into routine cancer care, making it an integral part of long-term cancer management strategies.

Finally, regulatory approvals and reimbursement support are also playing a significant role in market growth. The FDA and other regulatory bodies have started to approve MRD testing as part of routine clinical trials for cancer drugs, boosting the integration of MRD testing in both clinical research and practice. In addition, more insurance companies are covering MRD testing, further encouraging widespread adoption. As these factors continue to align, the MRD testing market is expected to continue its upward trajectory, driving innovation in cancer care and offering patients better chances of long-term survival and quality of life.

SCOPE OF STUDY:

The report analyzes the Minimal Residual Disease Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology, Other Technologies); Cancer Type (Hematological Malignancy, Solid Tumors); End-Use (Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Adaptive Biotechnologies Corporation
  • ArcherDX, Inc.
  • ARUP Laboratories Inc.
  • Asuragen Inc.
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health
  • Invitae Corporation
  • Invivoscribe Inc.
  • Labcorp Inc.
  • Laboratory Corporation of America Holdings
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoOne
  • QIAGEN N.V.
  • Quest Diagnostics
  • Sysmex Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Minimal Residual Disease Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Adoption of Personalized Oncology Testing Spurs Demand for MRD Assays
    • Rising Cancer Incidence and Recurrence Risk Throws the Spotlight on MRD Monitoring
    • Growing Focus on Early Cancer Detection Expands Addressable Market for MRD Technologies
    • Emergence of Liquid Biopsy as a Preferred Modality Accelerates Shift Toward Non-Invasive MRD Testing
    • Integration of MRD in Clinical Trial Endpoints Strengthens the Business Case for Advanced Assay Development
    • Regulatory Support for MRD as a Surrogate Endpoint Spurs Innovation and Investment
    • Inclusion of MRD Testing in Treatment Guidelines Drives Widespread Clinical Adoption
    • Rapid Advancements in NGS and dPCR Technologies Propel MRD Assay Sensitivity and Specificity
    • Strategic Collaborations Between Pharma and Diagnostic Companies Unlock New Commercial Pathways
    • Reimbursement Reforms and Coverage Expansion Generate Momentum for MRD Test Accessibility
    • Expanding Applications of MRD in Hematologic and Solid Tumors Opens New Growth Frontiers
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Minimal Residual Disease Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Minimal Residual Disease Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Minimal Residual Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Flow Cytometry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Flow Cytometry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Flow Cytometry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Next Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Next Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Next Generation Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals & Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hematological Malignancy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hematological Malignancy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hematological Malignancy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • JAPAN
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • CHINA
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • EUROPE
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Minimal Residual Disease Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Minimal Residual Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • FRANCE
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • GERMANY
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Minimal Residual Disease Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • INDIA
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Minimal Residual Disease Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Minimal Residual Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Minimal Residual Disease Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Minimal Residual Disease Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030
  • AFRICA
    • Minimal Residual Disease Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Minimal Residual Disease Testing by Technology - Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Minimal Residual Disease Testing by Technology - Percentage Breakdown of Value Sales for Flow Cytometry Technology, Polymerase Chain Reaction Technology, Next Generation Sequencing Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Minimal Residual Disease Testing by End-Use - Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Minimal Residual Disease Testing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Specialty Clinics, Diagnostic Laboratories and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Minimal Residual Disease Testing by Cancer Type - Hematological Malignancy and Solid Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Minimal Residual Disease Testing by Cancer Type - Percentage Breakdown of Value Sales for Hematological Malignancy and Solid Tumors for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제